http://biz.yahoo.com/rf/010307/n07469208_4.html

 

Wednesday March 7, 6:22 pm Eastern Time

U.S. panel doubts GlaxoSmithKline vaccine efficacy

(UPDATE: recasts; adds new information paragraphs 10-11, 13; edits)

By Lisa Richwine

 

BETHESDA, Md., March 7 (Reuters) - Drug giant GlaxoSmithKline Plc (quote

from Yahoo! UK & Ireland: GSK.L) did not prove that a children’s vaccine to

prevent five diseases was as effective as immunizing against the illnesses

separately, a U.S. advisory panel narrowly voted on Wednesday.

By a 6-5 vote, with one abstention, the panel said company studies failed

to show the vaccine could provide sufficient protection against all the diseases it was designed to prevent—diphtheria, tetanus, pertussis, hepatitis B and polio.

London-based GlaxoSmithKline, the world’s largest drug maker by sales, was

hoping to secure the panel’s support for U.S. marketing of the vaccine,

which would be the first in the United States to target five

life-threatening diseases with one series of shots given at two, four and

six months of age.

The product would reduce injections for the five diseases from nine to

three, lessening pain for children and making immunization schedules more

convenient for parents and doctors, the maker said. The company hopes to

sell the vaccine under the name Infanrix DTPa-HepB-IPV.

The Food and Drug Administration (FDA) advisory committee did not vote on

whether the vaccine was safe because there were “outstanding manufacturing

issues that need to be addressed,” panel chairman Robert Daum said.

The FDA has final say on whether to approve the product for U.S. marketing,

but the agency usually follows its panels’ advice.

Studies of more than 7,000 infants who received more than 20,000 doses of

Infanrix DTPa-HepB-IPV showed the vaccine spurred an immune response at least as strong as that seen with individual vaccines, GlaxoSmithKline officials said.

But many panel members said the most relevant study was too small to

clearly show that the combination vaccine worked as well as individual shots.

“As a pediatrician, I too appreciate the need for this vaccine, (but) I

don’t think the data we have been presented is adequate to support efficacy

at this time,” said Dr. Walter Faggett, a panel member.

Many panelists also expressed concern that 41 percent of infants given the

combination vaccine developed fevers, compared with 29.6 percent of

children who got separate shots. The company said most fevers disappeared

within a few days and did not lead to serious health problems.

But panel members “want more information about what the consequences are

for those increased rates of fevers,” Daum said.

GlaxoSmithKline spokeswoman Carmel Hogan said the company “remained

confident in the safety and (effectiveness)” of the vaccine and would

“work closely with the FDA to bring the vaccine to market as quickly as

possible.”

Hogan said she could not provide details of the manufacturing issues Daum

mentioned.

GlaxoSmithKline already sells a vaccine called Infanrix to prevent diphtheria, pertussis and tetanus.

 

 

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.